HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer

被引:92
|
作者
Lopez-Soto, A.
Folgueras, A. R. [2 ]
Seto, E. [3 ]
Gonzalez, S. [1 ]
机构
[1] Univ Oviedo, Dept Biol Func, IUOPA, Fac Med, E-33006 Oviedo, Spain
[2] Univ Oviedo, Dept Bioquim & Biol Mol, IUOPA, E-33006 Oviedo, Spain
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
关键词
ULBPs; NKG2D; HDAC3; tumour immunosurveillance; HISTONE DEACETYLASE INHIBITORS; I-RELATED CHAIN; NK CELLS; T-CELLS; RECEPTOR; SP3; CYTOTOXICITY; ACTIVATION; PROMOTER; SUSCEPTIBILITY;
D O I
10.1038/onc.2009.117
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The expression of the NKG2D ligands on cancer cells leads to their recognition and elimination by host immune responses mediated by natural killer and T cells. UL160-binding proteins (ULBPs) are NKG2D ligands, which are scarcely expressed in epithelial tumours, favouring their evasion from the immune system. Herein, we investigated the epigenetic mechanisms underlying the repression of ULBPs in epithelial cancer cells. We show that ULBP1-3 expression is increased in tumour cells after exposure to the inhibitor of histone deacetylases (HDACs) trichostatin A (TSA), which enhances the natural killer cell-mediated cytotoxicity of HeLa cells. Our experiments showed that the transcription factor Sp3 is crucial in the activation of the ULBP1 promoter by TSA. Furthermore, by small interfering RNA-mediated knockdown and overexpression of HDAC1-3, we showed that HDAC3 is a repressor of ULBPs expression in epithelial cancer cells. Remarkably, TSA treatment caused the complete release of HDAC3 from the ULBP1-3 promoters. HDAC3 is recruited to the ULBP1 promoter through its interaction with Sp3 and TSA treatment interfered with this association. Together, we describe a new mechanism by which cancer cells may evade the immune response through the epigenetic modulation of the ULBPs expression and provide a model in which HDAC inhibitors may favour the elimination of transformed cells by increasing the immunogenicity of epithelial tumours. Oncogene (2009) 28, 2370-2382; doi:10.1038/onc.2009.117; published online 11 May 2009
引用
收藏
页码:2370 / 2382
页数:13
相关论文
共 50 条
  • [41] Combination Doxorubicin and Interferon-α Therapy Stimulates Immunogenicity of Murine Pancreatic Cancer Panc02 Cells via Up-regulation of NKG2D ligands and MHC Class I
    Wang, Wen-Jia
    Qin, Si-Hao
    Zhang, Ji-Wei
    Jiang, Yue-Yao
    Zhang, Jin-Nan
    Zhao, Lei
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (22) : 9667 - 9672
  • [42] Transfer of the human NKG2D ligands UL16 binding proteins (ULBP) 1-3 is related to lytic granule release and leads to ligand retransfer and killing of ULBP-recipient natural killer cells
    Lopez-Cobo, Sheila
    Romera-Cardenas, Gema
    Garcia-Cuesta, Eva M.
    Reyburn, Hugh T.
    Vales-Gomez, Mar
    IMMUNOLOGY, 2015, 146 (01) : 70 - 80
  • [43] Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors
    Veneziani, Irene
    Infante, Paola
    Ferretti, Elisa
    Melaiu, Ombretta
    Battistelli, Cecilia
    Lucarini, Valeria
    Compagnone, Mirco
    Nicoletti, Carmine
    Castellano, Aurora
    Petrini, Stefania
    Ognibene, Marzia
    Pezzolo, Annalisa
    Di Marcotullio, Lucia
    Bei, Roberto
    Moretta, Lorenzo
    Pistoia, Vito
    Fruci, Doriana
    Barnaba, Vincenzo
    Locatelli, Franco
    Cifaldi, Loredana
    CANCER IMMUNOLOGY RESEARCH, 2021, 9 (02) : 170 - 183
  • [44] Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands
    Li, Geng
    Nikkhoi, Shahryar Khoshtinat
    Hatefi, Arash
    MEDICAL ONCOLOGY, 2023, 40 (04)
  • [45] Inhibition of Glycogen Synthase Kinase-3 Increases NKG2D Ligand MICA Expression and Sensitivity to NK Cell-Mediated Cytotoxicity in Multiple Myeloma Cells: Role of STAT3
    Fionda, Cinzia
    Malgarini, Giulia
    Soriani, Alessandra
    Zingoni, Alessandra
    Cecere, Francesca
    Iannitto, Maria Luisa
    Ricciardi, Maria Rosaria
    Federico, Vincenzo
    Petrucci, Maria Teresa
    Santoni, Angela
    Cippitelli, Marco
    JOURNAL OF IMMUNOLOGY, 2013, 190 (12) : 6662 - 6672
  • [46] The nuclear factor-κB pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-B inhibitors in cancer therapy
    Peinado, Carlos
    Kang, Xi
    Hardamon, Chanae
    Arora, Sumit
    Mah, Stephen
    Zhang, Hui
    Ngolab, Jennifer
    Bui, Jack D.
    IMMUNOLOGY, 2013, 139 (02) : 265 - 274
  • [47] Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways
    Park, Arum
    Yang, Yunjeong
    Lee, Yunhee
    Kim, Mi Sun
    Park, Young-Jun
    Jung, Haiyoung
    Kim, Tae-Don
    Lee, Hee Gu
    Choi, Inpyo
    Yoon, Suk Ran
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [48] Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer
    Han, Bin
    Mao, Fang-yuan
    Zhao, Yong-liang
    Lv, Yi-pin
    Teng, Yong-sheng
    Duan, Mubing
    Chen, Weisan
    Cheng, Ping
    Wang, Ting-ting
    Liang, Zhong-yuan
    Zhang, Jin-yu
    Liu, Yu-gang
    Guo, Gang
    Zou, Quan-ming
    Zhuang, Yuan
    Peng, Liu-sheng
    JOURNAL OF IMMUNOLOGY RESEARCH, 2018, 2018
  • [49] Suppression of Akt-mediated HDAC3 expression and CDK2 T39 phosphorylation by a bichalcone analog contributes to S phase retardation of cancer cells
    Hung, Kuang-Chen
    Lin, Meng-Liang
    Hsu, Shih-Wei
    Lee, Chuan-Chun
    Huang, Ren-Yu
    Wu, Tian-Shung
    Chen, Shih-Shun
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 829 : 141 - 150
  • [50] Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels
    Xu, Lijun
    Chen, XiaoDong
    Shen, MingJing
    Yang, Dong-Rong
    Fang, Laifu
    Weng, Guobin
    Tsai, Ying
    Keng, Peter C.
    Chen, Yuhchyau
    Lee, Soo Ok
    MOLECULAR ONCOLOGY, 2018, 12 (03): : 269 - 286